Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression
- 1 March 2000
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 14 (4), 397-403
- https://doi.org/10.1097/00002030-200003100-00013
Abstract
To investigate the virological and immunological impact of a structured treatment interruption (STI) in a cohort of HIV-1 chronically infected patients with a further long-lasting effective virus suppression. Twelve HIV-1 chronically infected adults who had maintained viral suppression ( 1 for a median time of 22 months, were included in the study. Participants interrupted their antiretroviral treatment during a maximum period of 30 days or until a viral load rebound > 3000 copies/ml was detected. The same prior antiretroviral regimen was resumed after STI. Kinetics of plasma viral rebound was evaluated every 2 days during the treatment interruption period. Flow cytometry and cell proliferation assays were performed before and after STI. Genotypic resistance was assessed at the time of treatment resumption. No adverse events occurred during the interruption period. In two patients no viral rebound was detected after 30 days of treatment interruption. In the remaining 10 patients, viral load became detectable (> 20 copies/ml) at a median time of 14 days after treatment interruption. Afterwards, viral load increased exponentially with a mean t1/2 of 1.6 days. Treatment was successfully resumed in all patients. No resistance-conferring mutations associated with the pre-interruption antiretroviral regimen were detected. The percentage of CD4 and CD8 lymphocytes did not vary during the STI period; however, the level of expression of T-cell activation antigen CD38 on CD8 T cells increased significantly in response to viral rebound. Four patients gained T-helper cell responses to recall antigens (tuberculin and tetanus toxoid), two of who developed an HIV-specific response to p24. STI in chronically HIV-1-infected patients is not associated with reductions in CD4 T lymphocytes or to clinical complications in this group of patients after 2 years of effective plasma viral suppression. Viral load rebounds in most but not all patients, without evidence of selection of resistance-conferring mutations. Thereafter, viraemia can be effectively controlled by antiretroviral agent reintroduction. HIV-specific T-helper cell responses may be achieved after one cycle of treatment interruption suggesting some degree of immune-stimulation. These data do not discard consecutive cycles of STI as a therapeutic strategy to boost HIV-specific immunity in order to maintain viral replication under effective control.Keywords
This publication has 20 references indexed in Scilit:
- HIV-1–specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapyJCI Insight, 1999
- Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapyAIDS, 1999
- Rate of HIV-1 RNA rebound upon stopping antiretroviral therapyAIDS, 1999
- HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatmentAIDS, 1999
- Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patientsAIDS, 1999
- In vivo HIV-1 replicative capacity in early and advanced infectionAIDS, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 diseaseThe Lancet, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- Positive Effects of Combined Antiretroviral Therapy on CD4 + T Cell Homeostasis and Function in Advanced HIV DiseaseScience, 1997